分類: 技術轉移招商

Latest news-English

Technology Available for Industry-Academia Collaboration or Technology Licensing. “DBPR901: a Humanized HSP90a Antibody with Anti-Desmoplasia Potency” (2022/11/18)

Technology Available for Industry-Academia Collaboration or Technology Licensing. “DBPR901: a Humanized HSP90a Antibody with Anti-Desmoplasia Potency” Date: 2022.11.18   1. Title: NHRI technology, “DBPR901: a …

閱讀更多 →
Latest news-English

Technology Available for Industry-Academia Collaboration or Technology Licensing. “DBPR22998: IsoQC inhibitor targeting CD47-SIRPa “Do not eat me” cancer immune checkpoint” (2022/11/18)

Technology Available for Industry-Academia Collaboration or Technology Licensing. “DBPR22998: IsoQC inhibitor targeting CD47-SIRPa “Do not eat me” cancer immune checkpoint” Date: 2022.11.18   1. Title: …

閱讀更多 →
Latest news-English

Technology Available for Industry-Academia Collaboration or Technology Licensing. “DBPR807: A CXCR4-Targeted Antagonist” (2022/7/26)

Technology Available for Industry-Academia Collaboration or Technology Licensing. “DBPR807: A CXCR4-Targeted Antagonist” Date: 2022.7.26   1. Title: NHRI technology, “DBPR807: A CXCR4-Targeted Antagonist” (abbreviated as “The …

閱讀更多 →
Latest news-English

Technology Available for Industry-Academia Collaboration or Technology Licensing. “An Aurora kinase inhibitor for precision targeting of MYC-amplified cancers” (2022/01/03)

1. Title: NHRI technology, “An Aurora kinase inhibitor for precision targeting of MYC-amplified cancers” (abbreviated as “The Technology”) available for industry-academia collaboration or technology licensing. …

閱讀更多 →
技術轉移招商en文章

Technology Available for Industry-Academia Collaboration or Technology Licensing. “Opioid Receptor Allosteric Modifier: DBPR116” (2021/1/28)

{:en} Title: NHRI technology, “Opioid Receptor Allosteric Modifier: DBPR116” (abbreviated as “The Technology”) available for industry-academia collaboration or technology licensing. Description: The Technology relates to …

閱讀更多 →